Trials show inactivated Zika virus vaccine is safe and immunogenic

(NIH/National Institute of Allergy and Infectious Diseases) The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR) are developing the vaccine and leading one of the trials. WRAIR also is co-funding the trials with the National Institute of Allergy and Infectious Diseases, part of NIH. The results will appear in The Lancet.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news